Gabriel Ángel Mecott-Rivera1, Jorge Alejandro Aguilar-Baqueiro2, Stephano Bracho3, Ivette Miranda-Maldonado4, Rodolfo Franco-Márquez5, Yanko Castro-Govea6, Edgar Gerardo Dorsey-Treviño7, Mauricio Manuel García-Pérez8. 1. Department of Plastic, Aesthetic, and Reconstructive Surgery, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, 64460, Monterrey, Mexico. Electronic address: gabriel.mecottrv@uanl.edu.mx. 2. Department of Plastic, Aesthetic, and Reconstructive Surgery, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, 64460, Monterrey, Mexico. Electronic address: drjorge.ab@hotmail.com. 3. Department of Plastic, Aesthetic, and Reconstructive Surgery, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, 64460, Monterrey, Mexico. Electronic address: braruiz.emm@gmail.com. 4. Department of Pathology, Faculty of Medicine, Universidad Autónoma de Nuevo León, 64460, Monterrey, Mexico. Electronic address: imiranda77@hotmail.com. 5. Department of Pathology, Faculty of Medicine, Universidad Autónoma de Nuevo León, 64460, Monterrey, Mexico. Electronic address: rancid2703@gmail.com. 6. Department of Plastic, Aesthetic, and Reconstructive Surgery, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, 64460, Monterrey, Mexico. Electronic address: goveayanko@hotmail.com. 7. Department of Plastic, Aesthetic, and Reconstructive Surgery, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, 64460, Monterrey, Mexico. Electronic address: dorsey.trevino@gmail.com. 8. Department of Plastic, Aesthetic, and Reconstructive Surgery, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, 64460, Monterrey, Mexico. Electronic address: drmauriciogarcia@gmail.com.
Abstract
BACKGROUND: Improving epithelialization of donor sites of split-thickness skin grafts (STSG) is extremely important in burned patients. We aimed to assess the efficacy of pirfenidone, a drug with anti-inflammatory, antifibrotic, and antioxidant effects, to accelerate wound healing. We hypothesized that pirfenidone accelerates the epithelialization rates in donor sites. METHODS: We included 28 patients requiring STSGs with donor sites of at least 7.5×10cm. After harvesting, the donor sites were randomly treated with either non-adherent gauze or topical pirfenidone and covered with non-adherent gauze. To assess epithelialization, biopsies were taken at day 7 and 10 on the pirfenidone group, and at day 10 on the control group. Percentage of epithelialization was assessed on the same days through clinical photographs. The pathologists and the clinical observer were blinded to the group and timepoint of the samples. RESULTS:24 patients were included in the study, with a median age of 21(5-73) for control group and 28(9-61) forpirfenidone. The thickness of epithelium was 75.10±60μm at day 10 for the control group; and 98.21±6μm at day 7, and 108±22μm at day 10 for the pirfenidone group (p=<0.05). Epithelization rate was 83.58±14.09% at day 10 for the control group; and 98.7±1.8% at day 7, and 99.5±1.6% at day 10 for the pirfenidone group. CONCLUSIONS:Pirfenidone is efficient in reducing the healing times when applied in STSG donor sites, at both days 7 and 10.
RCT Entities:
BACKGROUND: Improving epithelialization of donor sites of split-thickness skin grafts (STSG) is extremely important in burned patients. We aimed to assess the efficacy of pirfenidone, a drug with anti-inflammatory, antifibrotic, and antioxidant effects, to accelerate wound healing. We hypothesized that pirfenidone accelerates the epithelialization rates in donor sites. METHODS: We included 28 patients requiring STSGs with donor sites of at least 7.5×10cm. After harvesting, the donor sites were randomly treated with either non-adherent gauze or topical pirfenidone and covered with non-adherent gauze. To assess epithelialization, biopsies were taken at day 7 and 10 on the pirfenidone group, and at day 10 on the control group. Percentage of epithelialization was assessed on the same days through clinical photographs. The pathologists and the clinical observer were blinded to the group and timepoint of the samples. RESULTS: 24 patients were included in the study, with a median age of 21(5-73) for control group and 28(9-61) for pirfenidone. The thickness of epithelium was 75.10±60μm at day 10 for the control group; and 98.21±6μm at day 7, and 108±22μm at day 10 for the pirfenidone group (p=<0.05). Epithelization rate was 83.58±14.09% at day 10 for the control group; and 98.7±1.8% at day 7, and 99.5±1.6% at day 10 for the pirfenidone group. CONCLUSIONS:Pirfenidone is efficient in reducing the healing times when applied in STSG donor sites, at both days 7 and 10.
Authors: Patricia Liana Cristodor; Alexandru Nechifor; Silvia Fotea; Alin Codrut Nicolescu; Thomas Nadasdy; Yousef Bahloul; Alin Laurentiu Tatu Journal: Int J Gen Med Date: 2022-09-12
Authors: Adriana Martínez-Cuazitl; María Del Consuelo Gómez-García; Oriana Hidalgo-Alegria; Olivia Medel Flores; José Alberto Núñez-Gastélum; Eduardo San Martín Martínez; Ada María Ríos-Cortés; Mario Garcia-Solis; David Guillermo Pérez-Ishiwara Journal: Molecules Date: 2022-10-02 Impact factor: 4.927